We are contributing to the global fight against the coronavirus through our products and expertise in health and nutrition. Our corona ticker provides an up-to-date overview of our activities.
03:00 p.m. CEST: Can Food Supply Chains Cope with COVID-19?
From farmers and field workers, to food processors and retailers, the global pandemic is causing problems at every stage of the supply chain.
To understand the challenges the world faces, we spoke to leading experts on global food supply chains to ask: how are we preventing a health crisis from becoming a food crisis?
Read the full story in the Bayer Magazine.
09:00 a.m. CEST: Six Months That Will Change Global Food Security, One Way or the Other
COVID-19 has rocked economies and disrupted daily lives all over the world. Whether the global food system, especially in developing countries, emerges stronger or more fragile will depend on what happens next. For smallholder farmers in developing countries, the “end” of the coronavirus pandemic might be better described as the beginning of a new reality for agriculture.
03:00 p.m. CEST: COVID-19 demonstrates the increasing importance of digitalization
“Farmers, like everyone else, have had their normal business routines completely disrupted, and digital technologies have proven to be a life-line during this crisis.”
You can read the interview John Raines, CCO of The Climate Corporation gave EURACTIV on their website.
03:00 p.m. CEST: Digital Technology is Powering Agriculture in a Time of Crisis
“Successful global organizations cannot wait until a crisis emerges to uncover problems and pursue solutions. Bayer’s relentless, established pursuit of digital transformation has allowed us to not only adapt, but advance our operations while accounting for the current, unfortunate norms.” Read the whole article by Ingo Elfering, CIO, Head of Digital Transformation and Member of the Crop Science Executive Leadership Team on LinkedIn.
03:00 p.m. CEST: Virtual World Medical Innovation Forum - Healthcare Leaders Reflect on COVID-19
11,000 registrants representing 95 countries, 47 states and 3200 organizations joined the World Medical Innovation Forum on May 11.
In reaction to the global pandemic, the annual meeting had been turned into a one-day digital broadcast special on COVID-19 and infectious diseases.
Joerg Moeller, Head of Research & Development of our Pharmaceuticals Division and Mike Devoy, Chief Medical Officer of Bayer AG and Head Medical Affairs & Pharmacovigilance represented Bayer.
You can now watch the recordings of their sessions on YouTube.
Joerg Moeller about “Creating, Collaborating, and Accelerating Discovery During and After a Pandemic”
Panel discussion with Mike Devoy about “The Role of AI and Big Data in Fighting COVID-19”
08:00 a.m. CEST: Bayer donates more than €346,000 to mitigate the effects of the Coronavirus in Argentina
The donation will allow the incorporation of supplies, medical and security equipment in various hospitals and, in addition, funds will be allocated to the campaigns of the Argentine Red Cross and #Seamos Uno.
01:30 p.m. CEST: Launch of “Worldwide Empathy for Medics” Initiative
Healthcare professionals are facing unprecedented challenges at the forefront of the corona crisis. Experts point out the high risk for them of suffering from post-traumatic stress. A new international initiative "Worldwide Empathy for Medics" has just been launched to provide empathetic support and listening to healthcare professionals and all hospital workers and caregivers on the brink of coronavirus emergencies. Dr. Luc Peetermans from Belgium is behind this initiative, in collaboration with the Blabla Foundation, a training center specialized in communication and therapy as well as an international team of trainers in NonViolent Communication. As partner of healthcare professionals, Bayer supports this initiative and the medical profession in the fight against the coronavirus.
10:30 a.m. CEST: Bayer supports farmers in India with two initiatives
The Indian state of Maharashtra is famous for grape cultivation and its export quality grapes. Due to the restrictions caused by COVID-19, grape farmers are struggling to sell their produce. Bayer has stepped in to link grape farmers to offtakers such as DeHaat and AgriBazaar so that they can go on selling their products. To read more, find a Facebook post here.
Furthermore, Bayer India collaborates with India Post to enable smallholders to withdraw money. Due to the Covid-19 lockdown and related health & safety concerns, smallholders farmers in India are facing difficulties to withdraw cash from their Post Office savings accounts. Together with India Post, Bayer has set up a temporary kiosk with cash, biometric scanners and smartphones at one of its Better Life Farming Centers in Uttar Pradesh. More than 100 smallholders took the opportunity to carry out cash transactions and additionally received face masks and hand sanitizers from the Bayer team. To read more, find a Facebook post here.
01:00 p.m. CEST: Bayer to donate tablets of chloroquine for use in Italy
Based on a protocol signed with the AIFA (Italian Medicines Agency), Bayer will donate approximately one million chloroquine tablets for COVID-19 treatment in Italy.
AIFA’s Technical-Scientific Commission added chloroquine, along with other drugs, to the list of medicines for so-called off-label use outside of the established indications to treat patients with COVID-19 on March 13, 2020. Read more here.
04:00 p.m. CEST: Bayer Mexico produces and donates sanitizers and face shields. In the fight against COVID-19, Proquina, the site for pharmaceutical agents in Mexico, produces alcohol-based hand sanitizers. So far, a quantity of 1,000 liters has been generated, another 10,000 liters are currently in preparation.
In addition, a converted 3D printer in Lerma, Mexico, is now producing transparent face shields. Bayer donates both to hospitals, health centers and other health facilities in the country.
08:00 a.m. CEST: Starting today, Bayer will be distributing cloth masks to its employees. Every employee will be receiving four cloth masks that can be used as an additional health measure in places where there is significant community-based transmission. This can help employees in following existing or possible country guidance on continue wearing masks in public. Around 400,000 cloth masks will be available for employees. Bayer also donated masks to external partners, you can find an overview of our activities here in our Bayer magazine.
02:00 p.m. CEST: Our Canadian organization Bayer Inc., Mississauga, Ontario, will partner with the Population Health Research Institute (PHRI) in launching a major clinical research program aimed at identifying potential treatments against COVID-19. It will support the program with a financial commitment of CAD 1.5 million (approximately EUR 1 million) and the supply of products. Two studies will evaluate the safety and efficacy of different combination therapies including Bayer’s chloroquine and interferon beta-1b. It is planned to include more than 60 contributing research locations involving 6.000 patients.
02:00 p.m. CEST: Chinese radiologists share experience of treating COVD-19 patients with global peers. As the Coronavirus is still rampaging through the world, a medical academic webinar dedicated to sharing Chinese radiologists’ diagnosis experience of COVID-19 cases with their counterparts in 15 countries of Latin America, a continent also severely affected by the pandemic, was held on April 17th, joined by over 400 participants.
It was the 3rd webinar of an online medical academic forum series which is organized by the Chinese Radiology Society and China International Medical Foundation, and exclusively sponsored by Bayer China Radiology. With the purpose of promoting global solidarity in combating COVID-19, the forum series has 8 webinars and aims to connect radiologists around the world including Italy, Germany, Latin America countries and Asia-Pacific countries.
05:00 p.m. CEST: Bayer will donate nearly EUR 2 million to help fight the pandemic Covid-19 in France and Brazil.
1 million will be donated to the “All united against the virus” alliance set up by the Fondation de France, the Assistance Publique – Hôpitaux de Paris (AP-HP) hospital network and the Pasteur Institute. The money will enable the alliance to provide psychological support for caregivers, patients and their families as well as to improve the patient care pathway. It will also be used to fund research projects to better understand the coronavirus and the ongoing pandemic, and to develop antibody detection tests, effective treatments and vaccines. Read more here.
Furthermore, Bayer announces the donation of roughly EUR 1 million to help fight the pandemic in Brazil. We believe that collaboration is the key to deal with this crisis, so Bayer will allocate funds for three different initiatives: the Arrecadação Solidária, a Federal Government's project, the United Nations Children's Fund (UNICEF) and the purchase of safety items and hospital supplies. Read the whole news here.
05:00 p.m. CEST: To prevent Covid-19 from spreading in Senegal, the Bayer Foundation collaborated with its partners, the Senegal Ministry of Health and the health organization PATH. Together, they have redesigned the existing Bayer Foundation anti-malaria program to provide a quick Coronavirus response. In this LinkedIn article, PATH Country Director Aminatou Sar explains what that looks like.
12:00 p.m. CEST: Is Chloroquine, the active ingredient of the Bayer drug Resochin, a potential treatment for patients with Covid-19? Our Chief Medical Officer Michael Devoy and Matthias Berninger, Head of Public Affairs & Sustainability, talk about questions related to Resochin in a short video.
05:00 p.m. CEST: Bayer is supporting the fight against the corona pandemic in Spain with a comprehensive aid package. The company is donating €800,000 to the national health system in Spain for the purchase of urgently needed medical equipment and hospital beds.
Further contributions of more than €100.000 include the donation of test equipment for the diagnosis of Covid-19 to one of the research centers of Consejo Superior de Investigaciones Científicas (CSIC), a prestiogious public research institution, as well as support for the “Coronavirus Emergency in Spain" program of the Red Cross.
04:00 p.m. CEST: How does success look like in times of working remotely due to Corona? Our colleague Megan McNamee, Climate?Customer Success Specialist, discusses how her team at Climate Corp is staying connected and helping customers to make data driven decisions.
10:00 p.m. CEST: Employees all over the world can submit their ideas and challenges for the fight against Corona on our internal WeSolve collaboration platform. Together we can make an impact by leveraging our diverse resources - as experts, scientists, innovators or coaches, to keep working effectively and support each other in these difficult times. A first idea - how to help colleagues increase their resilience and mental wellbeing - has already been implemented.
03:00 p.m. CEST: In India, Bayer will be providing over 200,000 units of face masks (3 ply), 2000 units of N-95 masks, Personal Protective Equipment (PPE) kits and other medical supplies to various healthcare professionals in the country to help them in their fight against the virus. Furthermore, we are also helping other companies to engage in relief activities by helping them procure the PPE kits through our vendor network and helping to transport the same to various hospitals.
08:00 a.m. CET: While testing for COVID-19 ramps up, there’s another kind of testing that will prove equally important to combating the pandemic: one that can detect whether someone has already been infected and therefore is protected. Leapsmag has published a very interesting interview about this. Leapsmag was created by Leaps by Bayer, a new innovation initiative whose mission is to “aim for fundamental breakthroughs in the life sciences – ‘leaps’ that have the potential to change our world for the better.”
09:00 a.m. CET: Researchers at Bayer have launched an internal platform under the tagline “Science4Help”. All of our researchers are encouraged to use this platform to share and discuss ideas for combating the coronavirus, as a way of enabling us to leverage our in-house creative potential.
08:00 a.m. CET: Employees of the Pharmaceuticals Division with a medical background can register to volunteer in the fight against the coronavirus. Bayer is supporting the local health care system by giving these employees paid leave for a period of up to 4 weeks so that they can volunteer during this time. With numerous physicians and paramedical practitioners among its staff, Bayer is well positioned to help meet the urgent demand for specialist personnel.
03:00 p.m. CET: The WHO is launching a global study to test whether existing drug products can be used to treat corona. One of these products is Bayer’s active ingredient chloroquine (trade name: Resochin).
09:00 a.m. CET: We are assessing our capabilities for producing disinfectants, which are currently in such short supply, as a matter of urgency. In Germany we are drawing on the expertise of our plants in Wuppertal and Bergkamen. Our facility in Cimanggis, Indonesia, has decided to produce hand sanitizers locally to protect employees and their families. As of March 19th, they have already produced approximately 250 liters of disinfectants.
07:00 p.m. CET: Just recently it was announced that US health authorities will be supported in the fight against SARS-CoV-2 with the malaria drug chloroquine.
10:00 a.m. CET: Bayer CEO Werner Baumann addresses all of the company’s stakeholders in a message. He pledges that Bayer will remain a dependable partner for its customers throughout the current crisis and that it will support health authorities all over the world in the fight against the epidemic.
11:30 a.m. CET: Bayer’s Board of Management sends a letter to employees around the world and outlines the top priorities during the crisis: protecting their health and keeping production running so that we can continue to supply our products to people who need them. All employees able to work from home are asked to do so.